Table 3.

OR and 95% CI values of prostate cancer for T. vaginalis antibody serostatus in 691 matched pairs nested in the Health Professionals Follow-up Study, 1993 to 2000

Seronegative
Seropositive
Cases/controlsOR (95% CI)Cases/controlsOR (95% CI)*Multivariable-adjusted OR (95% CI)*,
Total prostate cancer604/6261.0087/651.41 (0.99-2.00)1.43 (1.00-2.03)
Organ-confined (≤T2 and N0M0)440/4551.0067/521.35 (0.91-2.00)1.36 (0.92-2.02)
Low-grade (Gleason sum <7)333/3421.0047/381.30 (0.81-2.09)1.27 (0.79-2.06)
High-grade (Gleason sum ≥7)210/2221.0033/211.67 (0.93-2.99)1.76 (0.97-3.18)
  • NOTE: Too few participants were diagnosed with advanced-stage prostate cancer (n = 62) to investigate its association with T. vaginalis antibody serostatus.

  • * Estimated by conditional logistic regression.

  • Adjusted for race (Caucasian, non-Caucasian) and cumulative family history of prostate cancer through 1996 (yes/no).